<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6612077\results\search\tropicalVirus\results.xml">
  <result pre="CentralLondon pmcid: 66120774226 doi: 10.1186/s12879-019-4226-6 : Research Article Prevalence of" exact="Zika" post="virus in blood donations: a systematic review and meta-analysis"/>
  <result pre="available in this article, unless otherwise stated. Abstract Background Transfusion-Transmitted" exact="Zika" post="virus (TT-ZIKV) has become an emerging threat to world"/>
  <result pre="to world blood banks due to the fast spread of" exact="ZIKV" post="epidemics and high rate of asymptomatic infections. For the"/>
  <result pre="high rate of asymptomatic infections. For the risk assessment of" exact="ZIKV" post="infection in blood products, relevant studies in blood donations"/>
  <result pre="relevant studies in blood donations or blood donors tested for" exact="ZIKV" post="were collected and analyzed systematically. The overall prevalence of"/>
  <result pre="ZIKV were collected and analyzed systematically. The overall prevalence of" exact="ZIKV" post="infection were estimated through meta-analysis and potential risk factors"/>
  <result pre="blood screening tests. Methods Relevant articles about the rate of" exact="ZIKV" post="detected in blood samples were identified from PubMed, Scopus"/>
  <result pre="samples) were included for meta-analysis. The overall pooled prevalence of" exact="ZIKV" post="(RNA and antibody) in blood donations was 1.02% (95%CI"/>
  <result pre="blood donations was 1.02% (95%CI 0.36–1.99). The pooled prevalence of" exact="ZIKV" post="RNA in blood donations was 0.85% (95%CI 0.21–1.88) less"/>
  <result pre="were more than two times likely to be infected by" exact="ZIKV" post="in Zika epidemic period (1.37, 95%CI 0.91–1.91) than in"/>
  <result pre="than two times likely to be infected by ZIKV in" exact="Zika" post="epidemic period (1.37, 95%CI 0.91–1.91) than in non-epidemic period"/>
  <result pre="antibodies (1.61, 95%CI 0.03–5.21) was almost twice as much as" exact="ZIKV" post="nucleic acid detected in blood donations (0.85, 95%CI 0.21–1.88)."/>
  <result pre="statistically significant differences were not observed. A total of 122" exact="ZIKV" post="positive blood donors were followed, of which 48 (39%)"/>
  <result pre="the 13 followed recipients reported any clinical symptoms related to" exact="Zika" post="infection posttransfusion. Conclusion The pooled prevalence of Zika infection"/>
  <result pre="related to Zika infection posttransfusion. Conclusion The pooled prevalence of" exact="Zika" post="infection in blood donations was 1.02%. The prevalence varied"/>
  <result pre="contains supplementary material, which is available to authorized users. Keywords" exact="Zika" post="virus (ZIKV) Blood donors/donations Blood screening tests Funding the"/>
  <result pre="China 31872499 Background As a zoonotic pathogens and reemerging arbovirus," exact="Zika" post="virus (ZIKV) has caught extensive attention since its outbreak"/>
  <result pre="caught extensive attention since its outbreak in Brazil 2015 [1]." exact="ZIKV" post="belongs to the genus Flavivirus, family Flaviviridae. It shares"/>
  <result pre="members such as dengue virus (DENV), yellow fever virus (YFV)," exact="West Nile" post="virus (WNV) and Japanese encephalitis virus (JEV) [2]. Approximately"/>
  <result pre="(WNV) and Japanese encephalitis virus (JEV) [2]. Approximately 80% of" exact="Zika" post="infections are asymptomatic [3, 4], the remainder usually develop"/>
  <result pre="fever, rash, arthralgia, myalgia, conjunctivitis and headache [5]. Nevertheless, sometimes" exact="ZIKV" post="infection can lead to much severer neurological complications, such"/>
  <result pre="Syndrome in adults [6, 7] and microcephaly in neonates [8]." exact="ZIKV" post="is transmitted to humans mainly through Aedes mosquitoes bite,"/>
  <result pre="activities, maternal-fetal pathway, physical contact and blood transfusion [3, 9]." exact="ZIKV" post="RNA has been detected in blood, semen, saliva, urine"/>
  <result pre="urine and other biofluids samples, but the viremia period of" exact="ZIKV" post="is not definite. It was estimated that the median"/>
  <result pre="the virus was detectable in blood for 9.9 days [10]. Notably," exact="ZIKV" post="RNA can persist in serum up to 54 days in"/>
  <result pre="infectors in viremia period can be a nonnegligible source of" exact="ZIKV" post="transmission and largely increase the risk that blood donations"/>
  <result pre="import of blood from low-risk regions; screening blood donations by" exact="ZIKV" post="NAT (Nucleic Acid Tests) and/or treating them with PRT"/>
  <result pre="PRT (Pathogen Reduction/inactivation Technology). On March 30, 2016, the first" exact="ZIKV" post="NAT assay for blood screening was permitted by FDA"/>
  <result pre="However, there are opposite attitudes towards mandating routine screening of" exact="ZIKV" post="in blood collections because it is time-consuming and costly."/>
  <result pre="time-consuming and costly. Some consider that the TT risk of" exact="Zika" post="in their country is low [15, 16], and there"/>
  <result pre="urgent need to introduce universal screening of donated blood for" exact="ZIKV" post="[17]. On the other hand, some studies mentioned that"/>
  <result pre="present measures were not effective enough to prevent transfusion of" exact="ZIKV" post="RNA-reactive blood products, and ZIKV NAT should be used"/>
  <result pre="enough to prevent transfusion of ZIKV RNA-reactive blood products, and" exact="ZIKV" post="NAT should be used [18, 19]. Their attitudes varied"/>
  <result pre="Their attitudes varied greatly depend on the prevalence rate of" exact="ZIKV" post="considered as low or high by different public health"/>
  <result pre="in different areas, but the cut-off value hasn’t been revealed." exact="ZIKV" post="TT risk modeling is not yet available to date"/>
  <result pre="to the absence of critical parameters [20] and US FDA" exact="Zika" post="guidance remained to be evaluated by a formal risk"/>
  <result pre="factors, but the foremost factor is the infection rate of" exact="ZIKV" post="in blood components, which should be a topic for"/>
  <result pre="first systematic review and meta-analysis to assess the prevalence of" exact="ZIKV" post="in blood donors or blood donations and find out"/>
  <result pre="eligible for next inspection as long as the survey of" exact="ZIKV" post="or arboviruses in human blood samples was mentioned in"/>
  <result pre="we went full-text screening and included studies that focused on" exact="ZIKV" post="infection in blood donors or donations. The detection of"/>
  <result pre="ZIKV infection in blood donors or donations. The detection of" exact="ZIKV" post="was confirmed by molecular or serological methods with RNA"/>
  <result pre="the time is during local Zika-epidemic), study area, number of" exact="ZIKV" post="infected samples (Event), total number of samples tested (Number),"/>
  <result pre="high quality = 8–11. Statistical analysis The proportion of samples infected with" exact="ZIKV" post="in each study was combined to give a pooled"/>
  <result pre="each study was combined to give a pooled prevalence of" exact="ZIKV" post="in blood donations. All analyses were performed with R"/>
  <result pre="2 largest blood centers 4 monthsa Puerto Rico 190 21,468 Cobas" exact="Zika" post="ID-NAT NM 7 p3 Gake2015 blood donors from six"/>
  <result pre="laboratories 2 months several states of United State 5 466,834 Procleix" exact="ZIKV" post="assay, RT-PCR, CDC IgM/IgG-ELISA 102 IU 7 p5 Borena2016 blood"/>
  <result pre="p6 Gallian2016 consecutive blood donations 5 monthsa Martinique 76 4129 RealStar" exact="Zika" post="virus RT-PCR Kit_1.1 2.1–6.5log10 copies/ml 6 p7 Slavov2016 volunteer"/>
  <result pre="Kuehnert2016 screened blood donations 2 monthsa Puerto Rico 68 12,777 Cobas" exact="Zika" post="NAT assay NM 4 p9 Adams2016 screened blood donations"/>
  <result pre="Adams2016 screened blood donations 3 monthsa Puerto Rico 143 18,163 Cobas" exact="Zika" post="NAT assay NM 4 p10 Aubry2013 volunteer blood donors"/>
  <result pre="ELISA NM 5 Note: aepidemic: the study period is during" exact="Zika" post="epidemic period NM not mentioned Of the 10 included"/>
  <result pre="(Cameroon):1 study. As to the detection methods, 7 studies detected" exact="ZIKV" post="RNA and 2 studies detected anti-ZIKV antibodies. One research"/>
  <result pre="moderate quality (mean score 5.4) (Table 1). Overall prevalence of" exact="Zika" post="virus in blood donations A total of 528,947 blood"/>
  <result pre="blood samples were tested in 10 literatures, the prevalence of" exact="Zika" post="virus in blood donations range from 0 to 4.89%,"/>
  <result pre="virus in blood donations range from 0 to 4.89%, and" exact="ZIKV" post="RNA detection rate range from 0 to 2.79%, ZIKV"/>
  <result pre="and ZIKV RNA detection rate range from 0 to 2.79%," exact="ZIKV" post="antibody seroprevalence range from 0.40 to 4.89%. All studies"/>
  <result pre="model was used to estimate the overall pooled prevalence of" exact="ZIKV" post="(RNA and antibody) in blood donations as 1.02% (95%CI"/>
  <result pre="2). Fig. 2 Forest plot of the pooled prevalence of" exact="ZIKV" post="in blood donations Prevalence of Zika virus in blood"/>
  <result pre="the pooled prevalence of ZIKV in blood donations Prevalence of" exact="Zika" post="virus in blood donations in different conditions As to"/>
  <result pre="it would be hard to deduce the prevalence trend of" exact="ZIKV" post="in recent years. But since the prevalence of Zika"/>
  <result pre="of ZIKV in recent years. But since the prevalence of" exact="Zika" post="virus in blood is presumably influenced by local endemic"/>
  <result pre="is identified in those studies: study conducted in areas where" exact="ZIKV" post="infection cases have been reported long ago but no"/>
  <result pre="cases have been reported (p5); and study collected samples before" exact="ZIKV" post="emergence (p10). Six studies (p1,p2,p6,p7,p8,p9) were performed when Zika"/>
  <result pre="before ZIKV emergence (p10). Six studies (p1,p2,p6,p7,p8,p9) were performed when" exact="Zika" post="is circulating and the pooled prevalence of Zika virus"/>
  <result pre="performed when Zika is circulating and the pooled prevalence of" exact="Zika" post="virus in blood donations was 1.37% (95%CI 0.91–1.91). Five"/>
  <result pre="in Asia. Stratified by detection method, the pooled prevalence of" exact="ZIKV" post="RNA in blood donations was 0.85% (95%CI 0.21–1.88) less"/>
  <result pre="of follow-ups In all included studies, a total of 122" exact="ZIKV" post="reactive blood donors were followed in three studies (p1:42,"/>
  <result pre="(p1, p4) have traced down to the recipients to whom" exact="ZIKV" post="reactive blood donations were transfused. Overall, among the 13"/>
  <result pre="(p1). None of recipients reported any clinical symptoms consistent with" exact="ZIKV" post="infection within 2 months of posttransfusion. Discussion Flavivirus transmission through"/>
  <result pre="Discussion Flavivirus transmission through blood transfusion has been recorded for" exact="Dengue" post="virus [33], West Nile virus [34], Yellow Fever vaccine"/>
  <result pre="through blood transfusion has been recorded for Dengue virus [33]," exact="West Nile" post="virus [34], Yellow Fever vaccine virus [35] and Zika"/>
  <result pre="West Nile virus [34], Yellow Fever vaccine virus [35] and" exact="Zika" post="virus [9, 36]. The major challenges in preventing transfusion-associated"/>
  <result pre="[9, 36]. The major challenges in preventing transfusion-associated transmission of" exact="ZIKV" post="are the high rate of asymptomatic infections and the"/>
  <result pre="a great threat to blood supply system with viremia of" exact="Zika" post="virus reaching to a high level exceeding 108copies/mL [27]."/>
  <result pre="high level exceeding 108copies/mL [27]. Therefore, an extensive investigation of" exact="ZIKV" post="prevalence in blood donations is quite essential to provide"/>
  <result pre="transfusion. Through this meta-analysis, we concluded the overall prevalence of" exact="ZIKV" post="in blood donations was 1.02%, which is higher than"/>
  <result pre="ZIKV in blood donations was 1.02%, which is higher than" exact="DENV" post="RNA (around 0.19% [38]~ 0.4% [39]) and CHIKV RNA (0.36–0.42%"/>
  <result pre="is higher than DENV RNA (around 0.19% [38]~ 0.4% [39]) and" exact="CHIKV" post="RNA (0.36–0.42% [40]) detected in blood donors, and much"/>
  <result pre="in terms of threats to US transfusion recipient safety [42]." exact="Zika" post="virus should also be classified as high-risk agent according"/>
  <result pre="its possible permanent neurological damage. Routine nucleic acid testing for" exact="WNV" post="was performed for all US donations in 2003 and"/>
  <result pre="for all US donations in 2003 and prevented thousands of" exact="WNV" post="transfusion-transmissions, more than 27 million donations were tested during"/>
  <result pre="27 million donations were tested during transmission periods with 1576" exact="WNV" post="RNA-positive donations identified [43], which is much lower than"/>
  <result pre="identified [43], which is much lower than the rate of" exact="ZIKV" post="prevalence in blood donations we summarized here. The virus"/>
  <result pre="in blood donations we summarized here. The virus load of" exact="ZIKV" post="in blood donations in included studies ranged from 102~107"/>
  <result pre="excluding vectorial transmission, the virus load is much higher than" exact="WNV" post="screened in blood donations [43]. Thus, since routine blood"/>
  <result pre="since routine blood screening test was already implemented for WNV," exact="ZIKV" post="should also be taken into consideration, especially in ZIKV-endemic"/>
  <result pre="(1.61%) in blood donation was almost twice as much as" exact="ZIKV" post="RNA prevalence (0.85%), this may due to antibodies can"/>
  <result pre="represent recent infections. On the contrary, a mere absence of" exact="ZIKV" post="nucleic acid in blood samples does not absolutely rule"/>
  <result pre="not absolutely rule out the existence of virus. So, both" exact="ZIKV" post="RNA and antibodies in blood donations implied risks in"/>
  <result pre="supply system. Here we calculated the overall pooled prevalence of" exact="ZIKV" post="including both ZIKV RNA and antibody, and then computed"/>
  <result pre="we calculated the overall pooled prevalence of ZIKV including both" exact="ZIKV" post="RNA and antibody, and then computed separately within each"/>
  <result pre="limited amount of studies in antibody detection. The prevalence of" exact="ZIKV" post="in blood donations during epidemic period (1.37%) was more"/>
  <result pre="infected because of the donors may have travel history to" exact="ZIKV" post="endemic areas, and get infected without notice before donation."/>
  <result pre="and get infected without notice before donation. Another possibility that" exact="ZIKV" post="has already transmitted into the study areas where are"/>
  <result pre="conducted in non-epidemic period, and three of them were detected" exact="ZIKV" post="antibodies. So, it’s also a possibility that false-positive results"/>
  <result pre="result shows that South America has the highest prevalence of" exact="ZIKV" post="in blood donations (2.17%), which is consistent with the"/>
  <result pre="donations (2.17%), which is consistent with the geographic distribution of" exact="Zika" post="infection [45, 46] and Brazil contributed most of the"/>
  <result pre="which can be attributed to the sporadic circulation history of" exact="Zika" post="in Africa [45]. Because of the high volume of"/>
  <result pre="to remote areas, as well as quickly-spread and large-scale of" exact="Zika" post="virus epidemics, it is not practical to import blood"/>
  <result pre="needed to guard blood supply safety. The existing blood donor-screening" exact="ZIKV" post="NAT assays demonstrate excellent sensitivity [47] and effectiveness. The"/>
  <result pre="assays demonstrate excellent sensitivity [47] and effectiveness. The risk of" exact="ZIKV" post="TT infection can be reduced greatly of 29% by"/>
  <result pre="that amustaline/glutathione treatment for red blood cells can effectively inactivate" exact="Zika" post="[48], Dengue [49] and Chikungunya virus [50], and other"/>
  <result pre="treatment for red blood cells can effectively inactivate Zika [48]," exact="Dengue" post="[49] and Chikungunya virus [50], and other methods aimed"/>
  <result pre="blood cells can effectively inactivate Zika [48], Dengue [49] and" exact="Chikungunya" post="virus [50], and other methods aimed at red blood"/>
  <result pre="Blood donations NAT screening and PRT were strongly suggested in" exact="Zika" post="virus-endemic areas. Given 39% of asymptomatic donors showed symptoms"/>
  <result pre="sanitary conditions and most importantly, the method used to detect" exact="ZIKV" post="infection and the diagnostic cutoffs adopted. In addition, the"/>
  <result pre="detailed subgroup analyses, we believe that the pooled prevalence of" exact="ZIKV" post="in blood donations calculated in this study are of"/>
  <result pre="(plasma, platelet, red cell and whole blood). With attention on" exact="ZIKV" post="increases, more research data are expected in the future"/>
  <result pre="intensive research. Conclusions Based on this meta-analysis, the prevalence of" exact="Zika" post="infection in blood donations is at high-risk level of"/>
  <result pre="areas. NAT blood screening tests and PRT are recommended in" exact="Zika" post="virus-endemic regions and appropriate strategies should be made according"/>
  <result pre="file 1: Figure S1. Forest plot of the prevalence of" exact="ZIKV" post="in blood donations in different epidemic situations of Zika."/>
  <result pre="file 2: Figure S2. Forest plot of the prevalence of" exact="ZIKV" post="in blood donations in different areas. (DOCX 84 kb)"/>
  <result pre="file 3: Figure S3. Forest plot of the prevalence of" exact="ZIKV" post="in blood donations detected by different methods. (DOCX 70"/>
  <result pre="NAT Nucleic Acid Test PRT Pathogen Reduction/inactivation Technology TT Transfusion-Transmitted/Transmission" exact="ZIKV" post="Zika virus Publisher’s Note Springer Nature remains neutral with"/>
  <result pre="Nucleic Acid Test PRT Pathogen Reduction/inactivation Technology TT Transfusion-Transmitted/Transmission ZIKV" exact="Zika" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
  <result pre="and preventionFront Microbiol20171108114 4.MoghadasSMShoukatAEspindolaALPereiraRSAbdirizakFet al.Asymptomatic transmission and the dynamics of" exact="Zika" post="infectionSci Rep201771582910.1038/s41598-017-05013-928724972 5.PetersenLRJamiesonDJPowersAMHoneinMAZika VirusN Engl J Med2016374161552156310.1056/NEJMra160211327028561 6.BritoFMAntunesDBCMoreiraAde MoraisMMHenriques-SouzaAet"/>
  <result pre="MoraisMMHenriques-SouzaAet al.Guillain-Barre syndrome, acute disseminated encephalomyelitis and encephalitis associated with" exact="Zika" post="virus infection in Brazil: detection of viral RNA and"/>
  <result pre="infectionAm J Trop Med Hyg20179751405140910.4269/ajtmh.17-010629140242 7.RozeBNajioullahFFergeJLDorleansFApetseKBarnayJLet al.Guillain-Barre syndrome associated with" exact="Zika" post="virus infection in Martinique in 2016: a prospective studyClin"/>
  <result pre="Dis20176591462146810.1093/cid/cix58829020245 8.MussoDGublerDJZika VirusClin Microbiol Rev201629348752410.1128/CMR.00072-1527029595 9.MottaIJSpencerBRCordeiroDSSArrudaMBDobbinJAet al.Evidence for transmission of" exact="Zika" post="virus by platelet transfusionN Engl J Med2016375111101110310.1056/NEJMc160726227532622 10.LesslerJOttCTCarcelenACKonikoffJMWilliamsonJBiQet al.Times"/>
  <result pre="transfusionN Engl J Med2016375111101110310.1056/NEJMc160726227532622 10.LesslerJOttCTCarcelenACKonikoffJMWilliamsonJBiQet al.Times to key events in" exact="Zika" post="virus infection and implications for blood donation: a systematic"/>
  <result pre="S.DoyleKateMunoz-JordanJorgeSantiagoGilberto A.KleinLiorePerez-PadillaJaniceMedinaFreddy A.WatermanStephen H.AdamsLaura E.LozierMatthew J.Bertrán-PasarellJorgeGarcia GubernCarlosAlvaradoLuisa I.SharpTyler M.Persistence of" exact="Zika" post="Virus in Body Fluids — Final ReportNew England Journal"/>
  <result pre="Medicine2018379131234124310.1056/NEJMoa161310828195756 12.WHO. Maintaining a safe and adequate blood supply during" exact="Zika" post="virus outbreaks. Interim guidance. February,2016. http://apps.who.int/iris/bitstream/handle/10665/204436/WHO_ZIKV_HS_16.1_eng.pdf.(accessed March 25, 2018)."/>
  <result pre="and product management to reduce the risk of transfusion-transmission of" exact="Zika" post="virus. https://strac.org/files/Infection%20Prevention/Zika_Guidance_for_Donors_Screening%202016,%20Feb.pdf. (accessed April 25, 2016). 14.US Food and"/>
  <result pre="Allows use of investigational test to screen blood donations for" exact="Zika" post="virus. March 2016. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm493081.htm. (accessed March 25, 2018). 15.Watson-BrownPViennetEHoadVCFlowerRFaddyHMIs"/>
  <result pre="Zika virus. March 2016. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm493081.htm. (accessed March 25, 2018). 15.Watson-BrownPViennetEHoadVCFlowerRFaddyHMIs" exact="Zika" post="virus a potential threat to the Australian blood supply?Aust"/>
  <result pre="infectious disease agents and blood safety in Australia: spotlight on" exact="Zika" post="virusMed J Aust20172061045546010.5694/mja16.0083328566073 17.BorenaWHoferTStiasnyKAberleSWGaberMvon LaerDet al.No molecular or serological"/>
  <result pre="to regions where Aedes albopictus circulatesPLoS One2017125e017817510.1371/journal.pone.017817528542611 18.MussoDNhanTRobinERocheCBierlaireDZisouKShan YanACao-LormeauVBroultJPotential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
  <result pre="Puerto Rico, April–august 2016Emerg Infect Dis201723579079510.3201/eid2305.16187328263141 26.GakeBVernetMALeparc-GoffartIDrexlerJFGouldEAGallianPet al.Low seroprevalence of" exact="Zika" post="virus in Cameroonian blood donorsBraz J Infect Dis201721448148310.1016/j.bjid.2017.03.01828549857 27.WilliamsonPCLinnenJMKesslerDAShazBHKamelHet"/>
  <result pre="Cameroonian blood donorsBraz J Infect Dis201721448148310.1016/j.bjid.2017.03.01828549857 27.WilliamsonPCLinnenJMKesslerDAShazBHKamelHet al.First cases of" exact="Zika" post="virus-infected US blood donors outside states with areas of"/>
  <result pre="Paulo state, Brazil, 2016Transfusion201757122897290110.1111/trf.1432228921551 30.KuehnertMJBasavarajuSVMoseleyRRPateLLGalelSAet al.Screening of blood donations for" exact="Zika" post="virus infection - Puerto Rico, April 3-June 11, 2016MMWR"/>
  <result pre="3-June 11, 2016MMWR Morb Mortal Wkly Rep2016652462762810.15585/mmwr.mm6524e227337368 31.AdamsLBello-PaganMLozierMRyffKREspinetCTorresJet al.Update: Ongoing" exact="Zika" post="Virus Transmission - Puerto Rico, November 1, 2015-July 7,"/>
  <result pre="transmitted by blood transfusionN Engl J Med2008359141526152710.1056/NEJMc070867318832256 34.PealerLNMarfinAAPetersenLRLanciottiRSPagePLet al.Transmission of" exact="West Nile" post="virus through blood transfusion in the United States in"/>
  <result pre="Mortal Wkly Rep, 2010. 59(2): p. 34–7. 36.Barjas-CastroMLAngeramiRNCunhaMSSuzukiANogueiraJSet al.Probable transfusion-transmitted" exact="Zika" post="virus in BrazilTransfusion20165671684168810.1111/trf.1368127329551 37.DuffyMRChenTHHancockWTPowersAMKoolJLet al.Zika virus outbreak on Yap"/>
  <result pre="threat to transfusion safetyTransfusion200949Suppl 21S29S10.1111/j.1537-2995.2009.02279.x19686562 43.DoddRYFosterGAStramerSLKeeping blood transfusion safe from" exact="West Nile" post="virus: American red Cross experience, 2003 to 2012Transfus Med"/>
  <result pre="2012Transfus Med Rev201529315316110.1016/j.tmrv.2015.03.00125841631 44.de VasconcelosZFMAzevedoRCThompsonNGomesLGuidaLet al.Challenges for molecular and serological" exact="ZIKV" post="infection confirmationChilds Nerv Syst2018341798410.1007/s00381-017-3641-529110196 45.BasileKKokJDwyerDEZika virus: what, where from"/>
  <result pre="45.BasileKKokJDwyerDEZika virus: what, where from and where to?Pathology201749769870610.1016/j.pathol.2017.08.00229050846 46.HillsSLFischerMPetersenLREpidemiology of" exact="Zika" post="virus infectionJ Infect Dis2017216suppl_10S868S87410.1093/infdis/jix43429267914 47.StoneMLanteriMCBakkourSDengXGalelSALinnenJMet al.Relative analytical sensitivity of"/>
  <result pre="and diagnostic real-time polymerase chain reaction assays for detection of" exact="Zika" post="virus RNATransfusion2017573pt273474710.1111/trf.1403128194799 48.LaughhunnASantaMFBroultJLanteriMCStassinopoulosAMussoDet al.Amustaline (S-303) treatment inactivates high levels"/>
  <result pre="virus RNATransfusion2017573pt273474710.1111/trf.1403128194799 48.LaughhunnASantaMFBroultJLanteriMCStassinopoulosAMussoDet al.Amustaline (S-303) treatment inactivates high levels of" exact="Zika" post="virus in red blood cell componentsTransfusion2017573pt277978910.1111/trf.1399328164306 49.AubryMLaughhunnASantaMFLanteriMCStassinopoulosAMussoDPathogen inactivation of"/>
 </snippets>
</snippetsTree>
